- Brands
- Offerings
- Diagnostic Panels
- Knowledge Center
- Diagnostics
Core Laboratory
Core Laboratory
Webinars
Access on demand presentations led by subject matter experts and Abbott key opinion leaders to gain insight into industry trends, medical discoveries, healthcare technologies and much more.
Watch now. Visit us frequently for new content.
UTILIZING IMMUNe RESPONSE INSIGHTS IN
THE MANAGEMENT OF COVID-19
After two years of the COVID-19 pandemic, the scientific community has reached a better understanding of the pathogen (SARS-CoV-2), the routes and modalities of transmission, and the clinical course. However, as our assumptions about the COVID-19 disease have and will continue to evolve, how do we leverage testing tools to be better prepared ahead of a likely resurgence of the infection in the future?
Immune profiles and the role of testing algorithms in combating sars-cov-2
Speaker
Deborah L. Birx MD.
Former White House Coronavirus Coordinator, USA
Deborah L. Birx, MD., received her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980 she trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology.
Dr. Birx has spent her first career serving the United States, as an Army Colonel and later, running some of the most high-profile and influential programs at the U.S. Centers for Disease Control and Prevention and U.S. Department of State. Among her many achievements, she led one of the most influential HIV vaccine trials in history (known as RV 144 or the Thai trial), which provided the first supporting evidence of any vaccine’s potential effectiveness in preventing HIV infection. In 2014, Dr. Birx became an Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy.
More recently, Dr. Birx served as the White House Coronavirus Response Coordinator, where she made recommendations to the Vice President using complex data integration to drive decision-making, as well as worked closely with state officials across the country to provide state-specific advice and guidance.
Dr. Birx has spent her first career serving the United States, as an Army Colonel and later, running some of the most high-profile and influential programs at the U.S. Centers for Disease Control and Prevention and U.S. Department of State. Among her many achievements, she led one of the most influential HIV vaccine trials in history (known as RV 144 or the Thai trial), which provided the first supporting evidence of any vaccine’s potential effectiveness in preventing HIV infection. In 2014, Dr. Birx became an Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy.
More recently, Dr. Birx served as the White House Coronavirus Response Coordinator, where she made recommendations to the Vice President using complex data integration to drive decision-making, as well as worked closely with state officials across the country to provide state-specific advice and guidance.
LEARNING OBJECTIVES
This 3-part webinar series aims to provide a comprehensive update on:
- How to better use diagnostics and data to ensure patients thrive in the time of COVID?
- Who is at risk for severe COVID disease, hospitalization and deaths?
- What tools and strategies are needed to proactively protect the most vulnerable?
- What gaps remain?
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RELATED PAGES
sars-cov-2 epidemiological dynamics and serologic responses to variants
Speaker
Charles Y. Chiu MD. PhD.
University of California, San Francisco, USA
Charles Chiu, M.D./Ph.D. is Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory.
Chiu currently leads a translational research laboratory focused on next-generation sequencing assay development for infectious disease diagnostics and investigation of the pathogenesis of and immune responses to emerging pathogens, including Borrelia burgdorferi (Lyme disease), enterovirus D68 in acute flaccid myelitis, Zika virus, and, most recently, the SARS-CoV-2 coronavirus. He is also developing new technologies such as nanopore sequencing and RNA-Seq transcriptome profiling to develop predictive models using machine learning for host response based diagnosis of infections.
Chiu’s work has been supported by funding from the National Institutes of Health (NIH), US Center for Disease Control and Prevention (CDC), Biomedical Advanced Research and Development Authority (BARDA), Abbott Laboratories, Chan-Zuckerberg Biohub, the Steven and Alexandra Cohen Foundations, and the California Initiative to Advance Precision Medicine.Dr. Chiu has authored more than 200 peer-reviewed publications (over 30 related to COVID-19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Inc., Biomesense, and Poppy Health, Inc.
Chiu currently leads a translational research laboratory focused on next-generation sequencing assay development for infectious disease diagnostics and investigation of the pathogenesis of and immune responses to emerging pathogens, including Borrelia burgdorferi (Lyme disease), enterovirus D68 in acute flaccid myelitis, Zika virus, and, most recently, the SARS-CoV-2 coronavirus. He is also developing new technologies such as nanopore sequencing and RNA-Seq transcriptome profiling to develop predictive models using machine learning for host response based diagnosis of infections.
Chiu’s work has been supported by funding from the National Institutes of Health (NIH), US Center for Disease Control and Prevention (CDC), Biomedical Advanced Research and Development Authority (BARDA), Abbott Laboratories, Chan-Zuckerberg Biohub, the Steven and Alexandra Cohen Foundations, and the California Initiative to Advance Precision Medicine.Dr. Chiu has authored more than 200 peer-reviewed publications (over 30 related to COVID-19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Inc., Biomesense, and Poppy Health, Inc.
LEARNING OBJECTIVES
- SARS-COV-2 structure, origin, and transmission
- COVID-19 – clinical manifestations and treatment
- Symptomatology of long COVID
- Available diagnostic testing options
- Available testing options (design and uses)
- How are emerging SARS-CoV-2 variants discovered, monitored, and why are they concerning?
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RELATED PAGES
immunology and immune responses to sars-cov-2
Speaker
.jpg)
Daimon P. Simmons MD. PhD.
Brigham and Women’s Hospital, USA
Dr. Simmons is a practicing Clinical Pathologist with research interests in autoimmune disease and inflammation. His clinical activities incorporate both immunology and molecular biology. He is currently the Associate Medical Director for the Brigham and Women’s Hospital Clinical Immunology Laboratory. He also is an attending physician on the Molecular Pathology service. He has authored and co-authored multiple publications regarding diagnostic testing.
Dr. Simmons also teaches immunology, molecular pathology, and microbiology at Harvard Medical School. His research activities have led to the discovery of a macrophage super-activation state that has broad implications for inflammatory human disease, and his research program focuses on dissection of pathways to target macrophage super-activation.
Dr. Simmons also teaches immunology, molecular pathology, and microbiology at Harvard Medical School. His research activities have led to the discovery of a macrophage super-activation state that has broad implications for inflammatory human disease, and his research program focuses on dissection of pathways to target macrophage super-activation.
LEARNING OBJECTIVES
- The innate and adaptive immune system both play a role in protection against respiratory infection
- Adaptive immune responses are defined by clonal diversity and clonal expansion
- Sterilizing immunity is a difficult goal dependent on microbial neutralization
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RELATED PAGES
Shining a spotlight on cytomegalovirus – focus on improving outcomes for mothers and babieS
Although significant advancements have been made in CMV diagnostic testing, universal screening during pregnancy has still not been substantially implemented or recommended. The burden of the disease related to congenital CMV is significant, as it is the leading non-genetic cause of hearing loss and neurodevelopmental disabilities in children. Despite its clinical significance, congenital CMV often goes undetected because many infected infants are asymptomatic at birth.1
While early diagnosis and intervention are fundamental, prevention of maternal infection, education and optimization of antiviral therapy can help to reduce the burden. This presentation highlights the clinical importance of congenital CMV infection, diagnosis, management, the developments in laboratory diagnostics, and how we can move forward to further reduce the impact of congenital CMV globally.
Speaker
Professor Sébastien Hantz MD. PhD.
Department of Bacteriology - Virology Hygiene
NRV for Herpesviruses, CHU Limoges, France
Professor Sébastien Hantz is a brilliant and recognized leader in virology and sexually transmitted infections concerning herpesviruses (CMV and HSV) and human papillomavirus. In addition to his Doctor of Medicine degree, he received his Ph.D. in 2009 from the University of Limoges, France. Currently, he is the Senior Medical Virologist, head of the Infectious Serology Department, and a Professor of Virology at Limoges University and Hospital of Limoges, France.
Since 2016, he has served as the Deputy Director of the National Reference Center for Herpesviruses. His research interest lies in congenital infections, sexually transmitted bacterial infections, and CMV resistance to antiviral therapies. With over 50 peer-reviewed publications, Professor Hantz has extensive research experience and has reviewed many manuscripts for numerous journals.
As a previous member of the National University Council (CNU 45-01), he actively recruited the future generation of assistant professors and presently coordinates two education units for research training at the University of Limoges. He also served as an expert for several French health agencies (INCa, ANSM, HAS) and has been on the advisory board for a vaccine manufacturer.
Since 2016, he has served as the Deputy Director of the National Reference Center for Herpesviruses. His research interest lies in congenital infections, sexually transmitted bacterial infections, and CMV resistance to antiviral therapies. With over 50 peer-reviewed publications, Professor Hantz has extensive research experience and has reviewed many manuscripts for numerous journals.
As a previous member of the National University Council (CNU 45-01), he actively recruited the future generation of assistant professors and presently coordinates two education units for research training at the University of Limoges. He also served as an expert for several French health agencies (INCa, ANSM, HAS) and has been on the advisory board for a vaccine manufacturer.
LEARNING OBJECTIVES
- Describe the clinical spectrum and outcomes of cCMV infections
- Realize the importance of screening/diagnosis and understand the role of diagnostics
- Recognize opportunities for prevention, management, and therapeutic strategies
WHO SHOULD WATCH
- Laboratorians
- Obstetricians & Gynecologists
- Infectious Disease Specialists
- Pediatricians
RELATED PAGES
1. Marsico, Concetta, and David W Kimberlin. “Congenital Cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment.” Italian journal of pediatrics vol. 43,1 38. 17 Apr. 2017, doi:10.1186/s13052-017-0358-8.
HEPATITIS C ELIMINATION STARTS WITH DIAGNOSIS
How do you eliminate a disease that 95% of people don't know they have?
Hepatitis C is called a silent killer because it often goes unnoticed for decades until serious liver damage has occurred. Diagnosing infected individuals is the first step in preventing the spread of Hepatitis C to others, in linking patients to curative therapies, and in driving overall awareness.
A healthier future without Hepatitis C is now possible, through innovations in science and technology. Watch the educational webinar to learn how clinical laboratory advancements can help make elimination a reality.
Speaker
Jean-Michel Pawlotsky
Professor of Medicine at the University of Paris-Est.
Prof. Jean-Michel Pawlotsky, MD., PhD. is a Professor of Medicine at the University of Paris-Est., Director of the National Reference Center for Viral Hepatitis B, C, and D, Director of the Department of Virology at the Henri Mondor University Hospital in Créteil France, Director of the Academic Department Viruses, Immunity, and Cancers.
LEARNING OBJECTIVES
- Discuss the importance of the clinical laboratory in reaching the World Health Organization’s elimination goals
- Understand recent guideline advancements that support Hepatitis C elimination
- Describe simplified diagnostic processes that support improved access to care
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RISK STRATIFICATION OF APPARENTLY HEALTHY POPULATION WITH ARCHITECT STAT HIGH SENSITIVE TROPONIN-I
In this webinar you will hear about a recently CE marked application for ARCHITECT STAT High Sensitive Troponin I, that aids in providing greater accuracy for estimation of risk for future cardiac events in apparently healthy people, when used in conjunction with clinical and diagnostics findings. Risk is classified as low, moderate or elevated and use of ARCHITECT STAT High Sensitive Troponin I, is supported by a large body of evidence. This simple blood test can aid in earlier intervention for high risk patients and may avoid unnecessary tests and treatments in low risk patients. ARCHITECT STAT High Sensitive Troponin I, is well known to many through its use in Emergency Departments where it has been trusted for many years to rule in or rule out Myocardial Infarction. This latest application sets the stage to support tackling the cardiovascular disease burden through prevention.
Speaker
Gillian Murtagh, MD.
Associate Medical Director, Diagnostics at Abbott
Dr. Murtagh is Associate Medical Director of Medical and Scientific Affairs for Abbott Diagnostics. Dr. Murtagh directs and implements clinical research activities, internal and external educational programs and business development projects in the cardiac space. Dr. Murtagh received her MD from Trinity College Dublin in 2003 before completing residency in Internal Medicine and specialty training in Cardiology (Advanced Cardiovascular Imaging and Cardio-Oncology at Northwestern Memorial and the University of Chicago).
Dr. Murtagh has been involved in cardiovascular biomarker research for over ten years. She was co-chair of the ACC Working Group in Cardio-Oncology and has authored and co-authored multiple publications on biomarkers and imaging. She joined Abbott Diagnostics Division as Associate Medical Director in 2015.
Dr. Murtagh has been involved in cardiovascular biomarker research for over ten years. She was co-chair of the ACC Working Group in Cardio-Oncology and has authored and co-authored multiple publications on biomarkers and imaging. She joined Abbott Diagnostics Division as Associate Medical Director in 2015.
LEARNING OBJECTIVES
- Understand the limitations of current risk assessment tools
- Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in predicting risk
- Understand the body of evidence
WHO SHOULD WATCH
- Laboratorians
- Endocrinologists
- Clinicians
- Metabolic Specialists
RELATED PAGES
Event: Esc preventive cardiology 2021
emerging role of cardiac biomarkers in cardiovascular risk stratification
In this webinar you can learn more about how the emerging role of cardiac biomarkers in cardiac risk stratification and how taking a patient centric approach through the additional use of high-sensitivity troponin I, in conjunction with other clinical diagnostic findings, can guide treatment and to help improve patient outcomes.
Speakers
Dr. Wolfgang Koenig
Dr. Luis Liete
Dr. Anoop Shah
Dr. Wolfgang Koenig, MD, FRCP, FACC, FAHA, FESC is a Professor of Cardiology. A former Director of the WHO-MONICA Augsburg Myocardial Infarction Registry, he has held multiple clinical positions at the University of Ulm Medical Center. In April 2015 he joined the Deutsches Herzzentrum München, where he is the Head of the Cardiometabolic Unit.
Dr. Luis Liete is currently an Interventional Cardiologist at CHUC (Coimbra, Portugal).
Dr. Anoop Shah is affiliated with London School of Hygiene and Tropical Medicine, London. His main research aims are to understand the epidemiological trends in the incidence and diagnosis of common cardiovascular pathologies. He is involved in multi-center cluster randomized clinical trials using 'big data' to evaluate how changes in health systems can improve outcomes in patients with cardiovascular disease. He maintains a keen research interest in global cardiovascular health especially in low- and middle-income nations.
LEARNING OBJECTIVES
- Learn about the benefits of using cardiac biomarkers to better stratify patients’ risk of a future cardiac event
- Understand limitations of classical risk stratification models and emphasizing the importance of customizing the approach to prevention of CVD
WHO SHOULD WATCH
- Cardiologists
- Primary Care Physicians
- Laboratorians
- Chief Medical Officer
RELATED PAGES
Explore
Build key laboratory competencies and explore topics from various disciplines with our learning guides.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Watch the webinar to hear from experts how you can realize the value within and beyond your laboratory walls with a TVO approach.